Complicated Intra-abdominal Infection Clinical Trial
Official title:
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections
Verified date | October 2018 |
Source | Cubist Pharmaceuticals LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus meropenem (1000mg q8h)for the treatment of adults with Complicated Intraabdominal Infections (cIAI).
Status | Completed |
Enrollment | 494 |
Est. completion date | October 15, 2013 |
Est. primary completion date | October 3, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnoses of cIAI. - Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous draining of an abscess) within 24 hours of (before or after) the first dose of study drug. Exclusion Criteria: - Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis; pancreatic abscess; or pelvic infections. - Complicated intraabdominal infection managed by staged abdominal repair (STAR), open abdomen technique including temporary closure of the abdomen, or any situation where infection source control is not likely to be achieved. - Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first dose of study drug, unless there is a documented treatment failure with such therapy. - Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity [e.g., daptomycin, vancomycin, linezolid] are allowed). - Severe impairment of renal function (estimated CrCl < 30 mL/min), or requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine output over 24 hours). - The presence of hepatic disease at baseline. - Considered unlikely to survive the 4 to 5 week study period. - Any rapidly-progressing disease or immediately life-threatening illness (including respiratory failure and septic shock). - Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any ß-lactam antibacterial (a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment), including cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole, or nitroimidazole derivatives. - Women who are pregnant or nursing. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cubist Pharmaceuticals LLC |
United States, Argentina, Bulgaria, Chile, Croatia, Estonia, Germany, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, Moldova, Republic of, Poland, Serbia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population | Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. | TOC; 26-30 days after start of study drug administration | |
Secondary | The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population | Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen | TOC; 26-30 days after start of study drug administration | |
Secondary | The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population | Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. | EOT; Within 24 hours of last study drug administration | |
Secondary | The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population | Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. | EOT; Within 24 hours of last study drug administration | |
Secondary | The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population | Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit. | LFU; 38 to 45 days after first study drug administration | |
Secondary | The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population | Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit | LFU; 38 to 45 days after first study drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
Completed |
NCT03293485 -
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
|
Phase 3 | |
Recruiting |
NCT05148702 -
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
|
Phase 3 | |
Completed |
NCT04927312 -
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
|
Phase 3 | |
Completed |
NCT00929643 -
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
|
N/A | |
Completed |
NCT01499290 -
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
|
Phase 3 | |
Completed |
NCT01147640 -
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
|
Phase 2 | |
Completed |
NCT01726023 -
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
|
Phase 3 | |
Completed |
NCT01644643 -
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
|
Phase 3 | |
Completed |
NCT01265784 -
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
|
Phase 2 | |
Withdrawn |
NCT00914888 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
Withdrawn |
NCT01602874 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00157898 -
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
|
Phase 4 | |
Recruiting |
NCT05733104 -
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
|
||
Completed |
NCT02739997 -
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
|
Phase 3 | |
Completed |
NCT03329092 -
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
|
Phase 3 | |
Completed |
NCT03217136 -
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
|
Phase 2 | |
Completed |
NCT01500239 -
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
|
Phase 3 |